The success of cell therapies hinges on not only proving that a product elicits the desired biological response, but also overcoming the challenges of manufacturing and administering a complex product to any patient.
Deal signed less than a month before the planned launch of the opioid-induced constipation (OIC) treatment for adults with chronic non-cancer pain.
A group of scientists at Texas Biomedical Research Institute have zeroed in on a new defense against HIV-1, the virus that causes AIDS.
Evotec said today it will join Sanofi in partnering with academic institutions to translate their research into new small-molecule drugs across multiple unspecified therapeutic...
A rationally designed drug-like protein interferes with the protein-protein interactions of PCNA, the so-called DNA clamp, offering a new way of hindering DNA replication in fast-proliferating cancer cells.
Through the acquisition, Otsuka will inherit Visterra’s Hierotope® platform, intended to design and engineer precision antibody-based therapies, and expand its pipeline with Visterra’s programs targeting infectious diseases, kidney diseases, cancer, and chronic pain.
Bolstering the immune system is not a new strategy when trying to protect against deadly pathogens, yet for those individuals that are immunocompromised, this...
A new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection.
A serochip-based blood test with multiplex capabilities has been designed to detect Lyme disease and/or one of seven other tick-borne diseases
Team says research results show existing safe-in-human broad-spectrum antivirals could be used on other viral infections.
Please wait while you are redirected to the right page...